Ginkgo Bioworks
DNA
190 hedge funds and large institutions have $2.68B invested in Ginkgo Bioworks in 2022 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 66 increasing their positions, 31 reducing their positions, and 43 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 31
71% more funds holding in top 10
Funds holding in top 10: 7 → 12 (+5)
63% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 43
16% more funds holding
Funds holding: 164 → 190 (+26)
0.44% less ownership
Funds ownership: 1.71% → 1.27% (-0.44%)
30% less call options, than puts
Call options by funds: $23.4M | Put options by funds: $33.5M
64% less capital invested
Capital invested by funds: $7.39B → $2.68B (-$4.71B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$284M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$104M |
| 3 |
Morgan Stanley
New York
|
+$50.8M |
| 4 |
HF
HRT Financial
New York
|
+$37M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$1.4B |
| 2 |
SIG
Senator Investment Group
New York
|
-$149M |
| 3 |
GA
General Atlantic
New York
|
-$101M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$94M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$37.4M |
DNA Hedge Fund Activity: Q1 2022 in Review
190 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q1 2022, worth a combined $2.68B — down 64% from $7.39B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new DNA positions and 43 closed out — a net gain of 27 holders — while 66 added to existing stakes and 31 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $284M. The largest seller was Viking Global Investors, cutting an estimated $1.4B.
- 190 institutional investors held Ginkgo Bioworks (DNA) as of Q1 2022, up from 164 in Q4 2021.
- Funds reported $2.68B of Ginkgo Bioworks stock for Q1 2022, down 64% quarter-over-quarter.
- 70 funds opened new Ginkgo Bioworks positions in Q1 2022 and 43 closed out, a net change of +27 holders.
- The largest Ginkgo Bioworks buyer in Q1 2022 was Baillie Gifford & Co, an estimated $284M added.
- The largest Ginkgo Bioworks seller in Q1 2022 was Viking Global Investors, an estimated $1.4B sold.
Based on aggregated 13F filings for Q1 2022.